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Overt carnitine palmitoyl transferase (CPTI) activity was measured in liver mitochondria from foetal rats 
(21 days gestation) and from neonatal rats (1 day post-partum). Birth was accompanied by a 6-fold increase 
in CPTl activity, a 14-fold decrease in sensitivity to inhibition by malonyl CoA and an increase in the nH 
and the So.5 for palmitoyl CoA. The activity of latent enzyme (CPTz) was unaffected at birth. 
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1. INTRODUCTION 
Many mammals, including the human and the 
rat, are subjected to a major change in nutrition at 
birth. In the foetal animal glucose, provided from 
the mother via the placenta, is the major oxidizable 
substrate. Non-esterified fatty acids are not con- 
sidered to be a fuel for the foetus since they do not 
readily cross the placental barrier and their concen- 
tration is low in foetal blood [ 1,2]. Furthermore, in 
normal circumstances, maternally-derived ketone 
bodies only provide a small proportion of foetal 
energy requirements [3]. At birth the transplacen- 
tal diet, high in carbohydrate, is replaced by the 
high-fat milk diet of suckling. Marked hyperketon- 
aemia is observed in new born infants [4,5] and in 
other mammals, including the rat [6-91. During 
the suckling period ketone bodies become major 
fuels for certain extrahepatic tissues including the 
brain [S]. It is therefore necessary for the neonatal 
liver to establish the capability for fatty acid oxida- 
tion and ketogenesis. A number of changes occur 
near to the time of birth which may contribute to 
the development of this capacity: 
(i) Increased levels of plasma non-esterified fatty 
acids [lo]; 
(ii) An increase in the hepatic carnitine content 
[IO,1 11; 
Foetal-neonatal transition Thyroid status 
(iii) Increased activity in hepatic mitochondria of 
carnitine palmitoyltransferase [7,12-161, ,& 
oxidation enzymes [15] and enzymes of the 
hydroxymethylglutaryl CoA pathway [17]; 
(iv) A substantial decrease in the plasma insu- 
lin/glucagon ratio [6,18]; 
(v) Increased gluconeogenesis [ 19,201 which may 
reduce oxaloacetate availability and hence 
divert acetyl CoA metabolism towards keto- 
genesis [2 11. 
The overt activity of carnitine palmitoyltransfer- 
ase (CPTI) in mitochondria from rat liver is 
potently inhibited by malonyl CoA [22,23]. Since 
the hepatic malonyl CoA content and the rate of 
fatty acid synthesis are closely correlated [23,24], 
this effect is thought to contribute to the mechan- 
ism whereby rates of hepatic fatty acid synthesis 
and oxidation are inversely related in a number of 
states [23]. It has also become apparent that the 
sensitivity of liver CPTl to malonyl CoA is altered 
in some conditions [25-301. In essence, the sensi- 
tivity of CPTl to malonyl CoA inhibition is higher 
and lower respectively in those states with in- 
creased and decreased hepatic malonyl CoA con- 
tents [29] thereby expanding the range of response 
of the enzyme to alterations in [malonyl CoA]. 
Although we are unaware of any actual measure- 
ments, it is likely that the hepatic malonyl CoA 
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content fails during the foetal-suckling neonatal 
transition since at this time there is a substantial 
decrease in fatty acid synthesis both in vitro [3 1,321 
and in vivo [7,33]. 
Here, we investigated changes in the activity and 
properties of hepatic CPTr during the foetal-neo- 
natal transition, paying particular regard to the 
sensitivity of the enzyme to malonyl CoA. 
2. MATERIALS AND METHODS 
Sources of chemicals are described in [25,30]. 
Liver mitochondria were isolated as in [34] using 
the following as sources: 
(9 
(ii) 
(iii) 
Single livers from fed pregnant Sprague- 
Dawley rats (20-21 days gestation). These had 
been mated as virgins when aged 13- 15 weeks. 
lo-12 pooled foetal livers (male and female) 
taken from the pups of the mothers used in (i). 
6-8 pooled livers from female rat pups on the 
first day after birth. These were allowed to 
suckle until the time of sacrifice. 
Mitochondria were finally suspended in 0.3 M suc- 
rose containing 10 mM Tris-HCl buffer (pH 7.4) 
and 1 mM EGTA and stored in ice. Mitochondrial 
protein was determined by the method in [35]. 
CPTr assays were performed within 30 min of 
the isolation of mitochondria. Aliquots (50~1) of 
intact mitochondria were incubated at 25°C for 
4 min in 1 ml assay mixtures to follow the incor- 
poration of [ 3H]carnitine into palmitoyl-[ 3H]car- 
nitine as in [30,36]. Mitochondrial protein concen- 
trations in these assays were: foetal, 243 f 26; neo- 
natal, 167 f 18; pregnant maternal, 210 + 17 
(means f SEM as pg/ml for 4 separate expt in each 
case). 
Total CPT activity was measured similarly using 
25 ~1 aliquots of mitochondria that had been soni- 
cated for 2 min at 2°C. 
CPTz activity was calculated by subtraction of 
CPTr from total CPT. 
Assays were linear with time and mitochondrial 
protein concentration. 
3. RESULTS AND DISCUSSION 
Fig. 1 shows that CPT2 maximal activity relative 
to mitochondrial protein was increased -6-fold be- 
tween the late foetal stage and the first day after 
birth. The scale of this increase is in accord with 
[PALMIT~YL COA] (PM) 
Fig. 1. Effect of palmitoyl CoA concentration on CPTi 
activities in foetal, neonatal and pregnant maternal rat 
liver mitochondria. L-Carnitine was present throughout 
at 400 PM. The values are means of 4 expt in each case. 
The bars indicate SEM: (0) foetal; (0) pregnant mater- 
nal; (0) neonatal; *, **, *** indicate P <0.02, <O.Ol 
and <O.OOl, respectively vs the maternal activity. Hill 
plots of the data from each of the individual experiments 
were in all cases good-fit straight lines (0.93< and 
<0.99) and were used to obtain nH and So.5 values (the 
concentration of palmitoyl CoA giving half-maximal 
CPTl activity) by regression analysis. These values were: 
foetal, nH = 2.23 f 0.09, So.5 = 23.4 + l.OpM; pregnant 
maternal, nH = 2.28 f 0.08, S0.s = 23.5 f 0.9 PM; 
neonatal, ,?H = 2.68 f 0.05 (P < 0.01 vs foetal), 
So.5 = 32.6 f 2.8 PM (P < 0.05 vs foetal). 
that reported in [12,15,16] in which similar assay 
methods were used. Since we have shown [37] that 
hepatic CPTr activity in fed pregnant rats is similar 
to that in non-pregnant adults, the maternal 
activity shown in fig. 1 may be taken as indicative 
of the normal adult activity. The CPTr activity in 
neonatal animals was about twice that of the adult 
value which, again, is in accord with earlier studies 
[15,16]. The nH and the So.5 for palmitoyl CoA ob- 
served under the present assay conditions for the 
enzyme in foetal rats were essentially identical with 
those for the adult. However, both these para- 
meters were significantly increased in the neonatal 
liver (legend to fig. 1). As a result of these changes, 
differences in the neonatal CPTr activity compared 
with those in the foetus or the adult are particularly 
accentuated at higher [palmitoyl CoA] . Previous 
studies have not investigated the relationship of 
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Table 1 
CPT2 activities (nmol . min-’ .mg protein-‘) in foetal, neonatal and pregnant maternal rat liver 
mitochondria 
[ palmitoyl CoA] 
20 ,uM 40 ,uM 60 pM 80 FM 
Foetal 
Neonatal 
Pregnant 
maternal 
3.79 f 0.57 6.39 f 0.60 5.64 f 0.14 3.91 f 0.47 
(6.53) (5.71) 4.59) 2.81) 
3.19 f 0.60 5.81 f 0.42 4.61 f 0.71 3.07 f 0.59 
(2.16) (1.17) (0.58) (0.39) 
4.73 -fr 0.48 7.50 f 0.82 6.98 + 0.70 4.95 * 0.50 
(3.28) (2.48) (1.90) (1.25) 
L-Carnitine was present throughout at 400 PM. Measurements were made with the same prepara- 
tions of mitochondria used for fig. 1. The values are means f SEM of 4 expt in each case. CPT2 
activity was calculated as in section 2. The values in parentheses represent he ratio CPT2/CPTr 
activity to [palmitoyl CoA] in these different 
states. 
Table 1 shows that these changes in CPT activity 
were confined to the overt, CPTr activity. The la- 
tent, CPT2, activity did not differ significantly be- 
tween the 3 states at any of the 4 tested [palmitoyl 
CoA]. This is essentially in accord with [38] but at 
variance with [16]. The observation that these 
CPT2 activities exhibited quite different profiles of 
activity vs [palmitoyl CoA] from those of CPTr 
(fig. 1) is in accord with other studies [39]. In 
essence, a substantially smaller proportion of the 
total CPT activity is overt in the foetal liver com- 
pared with the adult, whereas the opposite is 
observed in the neonatal animal. 
foetal to neonatal transition was accompanied by a 
substantial decrease in sensitivity to malonyl CoA 
(fig. 2). Under the present assay conditions ([pal- 
mitoyl CoA] and [albumin] both = 20pM), 50% 
inhibition of CPTr was obtained with 0.6pM in 
the foetal state whereas 9 PM malonyl CoA was 
necessary to achieve the same effect in the neonate. 
In fed adult animals, pregnancy may not greatly 
alter sensitivity to malonyl CoA [29,37]. There- 
fore, 5 ,uM malonyl CoA, which is necessary to 
achieve 50% inhibition of the pregnant maternal 
CPTr may also be taken as indicative of the situa- 
tion in the non-pregnant adult. We conclude that 
a decrease (-1Cfold) in sensitivity of CPTr to 
malonyl CoA is a further mechanism participating 
in the rapid development of fatty acid oxidative 
Fig. 2. Effect of malonyl CoA concentration on CPTr 
activities in foetal, neonatal and pregnant maternal rat 
liver mitochondria. L-Carnitine was present throughout 
at 400 pM and palmitoyl CoA at 20 PM. The values are 
means f SEM for 4 expt except where no error bar is 
shown, in which case the values are the means of 2 expt. 
The values are expressed as percentages of the activities 
in the absence of malonyl CoA which may be deduced 
from fig. 1: (0) foetal; (0) pregnant maternal; (0) 
neonatal. 
and ketogenic capabilities at birth. This change, 
coupled with the substantial increase in CPTr 
specific activity and the probable decrease in hepa- 
tic malonyl CoA content (see section 1) represents 
a powerful metabolic switching mechanism. 
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The hormonal, or other, factors responsible at 
birth for the increase in CPTI activity and the de- 
crease in malonyl CoA sensitivity are unknown. It 
is of interest however that the newborn rat is rela- 
tively hypothyroid [40,41] since the maturation of 
the hypothalamic-pituitary axis mainly occurs 
during the neonatal period. The foetal rat is similar 
to the hypothyroid adult in having a low CPTl 
activity but a ‘normal’ CPT2 activity [30]. Further- 
more, in the hypothyroid adult, the increase in 
CPTr activity in response to fasting is exaggerated 
[30]. Whether the glucose to fatty acid nutritional 
change together with the decrease in insulin/gluca- 
gon ratio at birth provides this system with a 
stimulus similar to that of fasting remains to be 
established. 
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